Dr. rer. nat. Marta Lustig

Facts

E-Mail: Marta.Lustig[at]uksh.de

Affiliations: Division of Stem Cell Transplantation and Immunotherapy / University Medical Center Schleswig-Holstein, Campus Kiel, Clinic for Internal Medicine II, Hematology and Oncology / University Medical Center Schleswig-Holstein, Campus Kiel

Address: Rosalind-Franklin-Str. 12, 24105 Kiel

Supervisor: Prof. Dr. med. Thomas Valerius

Curriculum vitae

Education/Training

Since 08/2024	PostDoc at the Division of Stem Cell Transplantation and Immunotherapy, University Medical Center Schleswig Holstein Kiel, (Germany)
09/2020-08/2024	PhD candidate at the Division of Stem Cell Transplantation and Immunotherapy, University Medical Center Schleswig Holstein Kiel, (Germany) “Improving myeloid cell activation by therapeutic monoclonal antibodies”
10/2019-06/2020	Master’s thesis at the Department of Internal Medicine II, Hematology and Oncology, Division of Stem Cell Transplantation and Immunotherapy, University Medical Center Schleswig Holstein Kiel, (Germany) “Inhibition of sialic acid-Siglec interactions improves myeloid cell activation by therapeutic monoclonal antibodies”
12/2018-02/2019	Student Research Assistant at Molecular Imaging North Competence Centre Kiel (MOIN CC) (Germany)
10/2016-02/2017 06/2017-09/2017	Bachelor’s thesis at the Centre of Advanced Biotechnology, Laboratory of Biotherapy at the San Martino Policlinic Hospital, Cancer Research, Genoa (Italy) “Potential role of ROBO1 in uveal melanoma progression”
02/2017-06/2017	Erasmus+ Traineeship Program at the Institute of Biochemistry, Faculty of Medicine, Leipzig University, Leipzig (Germany)

Research Experience/Academic Appointments

2018-2020	Master of Science – Medical Life Sciences Faculty of Medicine, Kiel University (Germany)
2014-2017	Bachelor of Science – Biotechnology Faculty of Biotechnology, University of Genoa (Italy)

Project-related publications

Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria.

Foss S, Sakya SA, Aguinagalde L, Lustig M, Shaughnessy J, Cruz AR, Scheepmaker L, Mathiesen L, Ruso-Julve F, Anthi AK, Gjølberg TT, Mester S, Bern M, Evers M, Bratlie DB, Michaelsen TE, Schlothauer T, Sok D, Bhattacharya J, Leusen J, Valerius T, Ram S, Rooijakkers SHM, Sandlie I, & Andersen JT.

PubMed (PMID: 38453922)

Nat Commun

2024

P4, P6, P7

Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells

Lustig M, Chan C, Jansen JH, Bräutigam M, Kölling MA, Gehlert CL, Baumann N, Mester S, Foss S, Andersen JT, Bastian L, Sondermann P, Peipp M, Burger R, Leusen JHW, Valerius T

PubMed (PMID: 37346044)

Front Immunol

2023

Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9

Chan C, Lustig M, Jansen JHM, Garcia Villagrasa L, Raymakers L, Daamen LA, Valerius T, Tetering Gv, Leusen JHW.

PubMed (PMID: 37444515)

Cancers (Basel)

2023

PREPRINT: Antibody-lectin chimeras for glyco-immune checkpoint blockade

Stark JC, Gray MA, Wisnovsky S, Ibarlucea-Benitez I, Riley NM, Ribi MK, Lustig M, Errington WJ, Bruncsics B, Sarkar CA, Valerius T, Ravetch JV, Bertozzi CR

bioRxiv - preprint

2022

Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?

Chan C, Lustig M, Baumann N, Valerius T, Tetering Gv, Leusen JHW.

PubMed (PMID: 35865547)

Front. Immunol.